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Protocol
AbstrACt
Introduction There is currently little evidence for the 
optimal dosing strategy of four-factor prothrombin complex 
concentrates (PCC) in vitamin K antagonist (VKA)-related 
bleeds. The generally accepted dosing strategy is the use of a 
variable dose calculated using patient-specific characteristics 
as per manufacturer’s instruction. However, evidence exists 
that the use of a fixed low dose of 1000 international units 
of factor IX (IU fIX) might also suffice. Recent studies indicate 
that in terms of haemostatic effectiveness, the fixed dosing 
strategy might be even superior to the variable dosing 
strategy. The PROPER3 (PROthrombin complex concentrate: 
Prospective Evaluation and Rationalisation, number 3) study 
aims to confirm the non-inferiority, and explore superiority, in 
haemostatic effectiveness of the fixed PCC dosing strategy 
compared with the variable dosing strategy in VKA-related 
extracranial bleeding emergencies.
Methods and analysis The study is designed as a 
randomised controlled multicentre non-inferiority trial. 
Eligibility criteria are an indication for PCC due to VKA-
related extracranial bleeding in subjects 18 years of age 
or older. The control group will receive a variable dose, 
determined by patient-specific bodyweight and international 
normalised ratio. The intervention group is dosed a fixed 
1000 IU fIX PCC. Primary outcome is the haemostatic 
effectiveness of both treatments, as defined by the 2016 
International Society on Thrombosis and Haemostasis (ISTH) 
criteria. The sample size is set at 155 patients per treatment 
arm, requiring 310 patients in total. Non-inferiority on the 
proportion (risk) difference of the primary outcome will be 
evaluated using the asymptotic Wald test for non-inferiority. 
The non-inferiority margin is set at 6%. The primary analysis 
will be based on the per-protocol population.
Ethics and dissemination Study results will be published 
in an international journal, communicated to discipline-
specific associations and presented at (inter)national 
meetings and congresses.
trial registration number EUCTR2014-000392-33; Pre-
results.
rAtIonAlE 
Vitamin K antagonists (VKAs) are used 
by millions of users worldwide as oral 
anticoagulation therapy. Although highly 
effective, risk of bleeding is an important 
limitation.1 2 The annual risk of major bleeding 
is thought to be between 1 and 3 events per 
100 patient years,3 4 although recent studies 
demonstrate incidences ranging from 2.7 
to 7.5 events per 100 patient years.5–7 When 
a major bleed occurs, rapid reversal of VKA 
is required. For this indication, four-factor 
prothrombin complex concentrate (PCC) is 
the agent of choice.8 
PCC is a lyophilised concentrate of vitamin 
K dependent coagulation factors, made from 
human donor plasma. It has been in routine 
clinical use in the Netherlands since 1973. 
However, debate continues about the optimal 
strengths and limitations of this study
 ► This randomised controlled trial will provide 
definitive evidence on the effectiveness of the low 
fixed dose of 1000 international units of factor 
IX (IU  fIX)   prothrombin complex concentrate 
(PCC) compared with the variable dose as per 
manufacturers instruction, in vitamin K antagonist 
(VKA)-related bleeding.
 ► The study uses a standardised definition for 
haemostatic effectiveness as primary outcome, as 
defined by the International Society on Thrombosis 
and Haemostasis.
 ► The design is optimised to require minimal study-
related effort from treating physicians while exposing 
participating patients to almost no additional burden.
 ► A deferred consent procedure is used to minimise 
study-related delay in treatment as PCC for VKA-
related bleeding is an emergency situation, therefore 
allowing capturing of all eligible patients.
 ► A complicating factor might be the wide variety 
of medical disciplines and physicians involved 
in treatment of VKA-related bleeds, which might 
hamper inclusion rates.
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dosing strategy.9 10 Elements to consider are efficacy 
regarding cessation of bleeding and also risk of throm-
botic complications of PCC as well as speed and ease of 
administration in an emergency setting and costs.11
The generally accepted dosing strategy is, per manu-
facturers instruction, dose-calculation based on specific 
patient characteristics such as bodyweight, international 
normalised ratio (INR) at presentation and desired target 
INR (variable dosing strategy). While guidelines advise 
positively on using PCC, they do not discuss the dosing 
strategy.12–15
Concurrently, a fixed PCC dosing strategy of 1000 inter-
national units of factor IX (IU fIX) is increasingly used in 
clinical practice. Our pilot study in 2011 demonstrated 
in a before-and-after design little difference in both INR 
reduction and clinical outcome when comparing the 
fixed dosing strategy to the variable dosing strategy.16 A 
subsequent prospective observational study in extracra-
nial bleeding, in which one hospital using a fixed dosing 
strategy of 1000 IU fIX was compared with a similar 
hospital using the variable dosing strategy, demon-
strated that the variable dose performed better based on 
reduction in INR (primary outcome).17 However, when 
successful clinical outcome was considered, the fixed dose 
did not perform worse (96% successful clinical outcome 
in the fixed dose vs 88% in the variable dose).
The main limitation of the study was the lack of rando-
misation, making this study vulnerable to bias. Although 
both patient groups and hospitals were similar in all char-
acteristics considered, a difference in baseline risk could 
not be excluded. Furthermore, the study was not powered 
on clinical outcome.
In summary, additional evidence is needed to substan-
tiate that the fixed dosing strategy of PCC is at least as 
clinically effective as a variable dose. We are therefore 
performing the PROPER3 study (PROthrombin complex 
concentrate: Prospective Evaluation and Rationalisation, 
number 3), a randomised controlled multicentre trial to 
confirm the non-inferiority in clinical efficacy of the fixed 
dose in a randomised setting.
objECtIvEs
The primary objective of this study is to test whether the 
clinical outcome, defined as haemostatic effectiveness, of 
a fixed PCC dose is non-inferior to the variable PCC dose, 
for VKA-related bleeding in a randomised multicentre 
setting. The non-inferiority design was selected because 
if the fixed dose proves to be equally effective, it intro-
duces several advantages over the variable dose. These 
advantages are easier and quicker administration of an at 
average lower PCC dose, not requiring dose calculations 
or specific lab data, a theoretically lower risk of throm-
botic complications and as such favouring cost-effec-
tiveness. If non-inferiority is demonstrated, a secondary 
analysis for superiority is planned.
Secondary objectives are to compare INR as a surro-
gate endpoint as well as the variables time to PCC 
administration, total PCC dose, thrombotic complica-
tions, length of hospital/ICU stay, additional procedures 




The study is designed as a randomised controlled non-in-
feriority trial, comparing the 1000 IU fIX fixed PCC dose 
strategy to the variable dose PCC to counteract VKAs in 
extracranial bleeding emergencies. Patient enrolment 
started in October 2015 and is expected to end in 2019.
The study will mainly take place in the emergency 
departments of eight large Dutch academic or teaching 
hospitals. A wide variety of medical disciplines will be 
involved in the study with the bleeding site determining 
the treating disciplines. In the Dutch clinical setting, 
four-factor PCC is the agent of choice for VKA reversal 
in bleeding emergencies where vitamin K administration 
alone is not an option. National guidelines advise against 
the use of plasma or other factor concentrates such as 
three-factor PCC or activated PCC for this indication.18 
Patients enter the study as soon as the treating physician 
decides to order PCC; the decision itself to use PCC is not 
part of the study, nor is the PCC supplied by the study.
Eligibility criteria
The study focuses on dose optimisation of PCC in the 
management of extracranial bleeds in adult VKA users. 
Eligibility criteria therefore are (1) an indication for PCC 
due to VKA related bleeding, (2) bleeding is extracranial 
and (3) subject has to be 18 years or older of age.
Exclusion criteria
Exclusion criteria are: (1) Intracranial bleeding, (2) PCC 
indication(s) not related to bleeding (eg, urgent reversal 
in patients without bleeding), (3) PCC indication(s) 
not related to VKA and (4) previous participation in the 
study. The exclusion of intracranial bleeds in the current 
study is based on the lack of pilot data supporting the use 
of a fixed dose.19
Intervention
Two PCC dosing strategies will be compared in this study. 
The intervention group will receive a fixed dose of 1000 
IU fIX PCC. The control group will receive a variable dose 
PCC, determined per manufacturer’s instructions. In 
detail, the variable dose is determined either using body-
weight, baseline INR and target INR (Cofact, Sanquin) 
or using just bodyweight and baseline INR (Beriplex/
KCentra, CSL Behring and Octaplex, Octapharma). See 
also figure 1 for examples of dose calculation algorithms. 
The study is open for all PCC brands registered in the 
Netherlands with participating brands depending on 
local hospital policy and all brands being four-factor PCC.
As mentioned before, the decision to use PCC is at the 
discretion of the treating physician. All treatment aspects 
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other than the PCC dosing strategy, such as the use of 
vitamin K or packed red blood cells (PRBCs), should 
agree with routine clinical practice. This approach was 
chosen because PCC use and other treatment aspects are 
highly regulated in the Netherlands by local treatment 
protocols and national guideline.18 In this way, the study 
solely intervenes in PCC dose for a proper comparison.
recruitment and allocation
After deciding to use PCC for a patient fulfilling the eligi-
bility criteria, the treating physician then can randomise 
the PCC dosing strategy by telephone. Telephone-rando-
misation was chosen because it requires the least amount 
of effort from the treating physician. In addition, it is 
the quickest way to allocate a treatment to the patient, 
which is crucial to reduce study-related interference in 
the time to emergency PCC infusion. Finally, using this 
centralised randomisation maximises allocation conceal-
ment pre-randomisation, preventing potential selection 
bias.
For randomisation GCP-validated ALEA V.15.1 soft-
ware (FormsVision BV, the Netherlands) is used. 
Permuted-block randomisation with 1:1 allocation is 
used, stratified per participating centre. Blinding is not 
attempted; treatment allocation is open to the treating 
physician and the patient after randomisation.
Escape medication
If the dose of PCC allocated in the study is deemed not, 
or not sufficiently, effective, additional PCC dosing is left 
to the treating physician’s discretion. The treating physi-
cian is not limited to a certain timeframe for this decision. 
When additional PCC is necessary however, the studied 
treatment for this subject will fail to meet the primary 
endpoint (ie, no good haemostatic effectiveness reached).
deferred consent
After a stable condition and situation has been reached, 
informed consent is sought as soon as possible using a 
deferred consent procedure. As approved by the ethics 
committee, a regular informed consent procedure, 
executed before the study intervention, would harm the 
patient as the emergency setting of VKA related bleeding 
does not allow time loss before administration of PCC. As 
both treatment arms represent a dosing strategy that is 
routinely used in Dutch clinical practice and local guide-
lines, randomisation with deferred consent was consid-
ered ethical.
Figure 1 PCC dose per manufacturer’s instructions. For Cofact (Sanquin), the variable dose is determined using bodyweight, 
baseline INR and a choice in a preferred target INR of ≤2.1 (A) or ≤1.5 (B). For Beriplex (CSL Behring), the manufacturer’s 
instructions only provide a dosing algorithm to reach a target INR≤1.3 (C). For both Cofact and Beriplex, 10 mL corresponds to 
250 IU fIX. INR, international normalised ratio; IU fIX, international units of factor IX; PCC, prothrombin complex concentrate. 
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Deferred consent is asked from a proxy if the patient 
is incapable of giving consent personally. For patients or 
proxies who do not give informed consent, data will not 
be used. If a randomised patient deceases before being 
able to give consent, patient data will be used for study 
purposes to avoid bias.
Primary outcome
The primary outcome is the proportion of patients with 
successful clinical outcome, defined as good haemostatic 
effectiveness, assessed over 24 hours from the end of infu-
sion. Haemostatic effectiveness is defined according to 
the International Society on Thrombosis and Haemostasis 
(ISTH) SSC 2016 criteria for assessment of effectiveness 
of major bleeding management.20 See figure 2 for details 
of the definition. In summary, haemostasis is considered 
effective when a visible bleeding is stopped within 4 hours. 
For a musculoskeletal bleed, there has to be pain relief 
and improvement in swelling within 24 hours. Effective 
haemostasis in non-visible bleeds is reached if the haemo-
globin level has not decreased more than 10% at 48 hours 
compared with the level at initial treatment. For all types 
of bleeds, an additional requirement for haemostasis to 
be considered effective is that invasive interventions (eg, 
fasciotomy, endoscopy) were either not necessary or had 
no bleeding complications.
Necessary data for assessment of the haemostatic effec-
tiveness will be collected. With this, data an indepen-
dent endpoint adjudication board (EAB), blinded to the 
treatment strategy, will adjudicate the effectiveness of the 
treatment. The EAB consists of two doctors of internal 
medicine, who will independently adjudicate the cases at 
first and in case of disagreement seek consensus.
secondary outcomes
 ► INR, before and 60 min after the end of PCC 
administration.
 ► Time between admission to emergency room and 
start of PCC administration (door-to-needle time).
 ► Repeated dosing and total administered dose of PCC.
 ► Mortality in-hospital and at 30 days after PCC 
administration.
 ► Thrombotic complications.
 ► Major bleeding complications.
 ► Length of (ICU) hospital stay.
 ► Additional procedures to reach haemostasis.
sample size
A sample size of 282 patients was calculated to evaluate 
non-inferiority of the primary endpoint. The study will 
however include a total of 310 patients to allow for loss 
to follow-up or patients not evaluable for the primary 
endpoint. For calculation, first an actual between-group 
difference of 4% in proportion of patients with effective 
haemostasis was assumed. This assumption was estimated 
conservatively from the between group risk difference 
of 8.3% seen in the highly analogous previous study.17 
Second, a non-inferiority margin difference of 6% was 
deemed clinically acceptable after debate with interna-
tionally renowned haematologists and in comparison to 
previous studies.8 17 PASS software V.11.0.10 (NCSS, Kays-
ville, Utah, USA) was used to calculate the sample size 
using the unpooled one-sided Z test, using a required 
power of 80% and a alpha (one-sided) of 0.025.
data collection and management
For every included patient, there are two case report 
forms (CRFs) to complete. The acute phase CRF serves 
to capture data in the acute situation (ie, around PCC 
administration) and has to be completed by the treating 
physician. Only data that are at risk of not being routinely 
collected are captured by this CRF, such as dose and time 
of infusion of PCC and other interventions like vitamin K 
or PRBCs. A paper version was chosen because the emer-
gency situation will not allow the treating physician time 
to comprehend digital CRF systems. The second CRF 
collects all other relevant data and is completed by study 
investigators.
The first CRF will possibly contain patient identifying 
information and thus will be stored locally in the hospital 
Figure 2 Schematic representation of ISTH proposed definitions for effective haemostasis in management of major bleeding.18 
ISTH, International Society on Thrombosis and Haemostasis.
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that included the patient. The second CRF does not 
contain patient identifying information and is stored 
centrally at the site of the study coordinator. For study 
purposes, all data will be handled and processed anony-
mously. Paper CRF data, excluding any patient identifying 
information, is subsequently entered in OpenClinica clin-
ical trial data management software V.3.11 (OpenClinica, 
Waltham, Massachusetts, USA).
statistical methods
For statistical analysis, we will perform formal hypoth-
esis testing on non-inferiority of the primary outcome, 
clinical outcome being defined as effective haemostasis, 
between the fixed and the variable dosing strategy. For 
this, the asymptotic Wald test for non-inferiority will be 
used to analyse non-inferiority on the proportion (risk) 
difference. Asymptotic Wald confidence limits will also be 
calculated. Analysis will be based on the population that 
complied with the allocated dosing strategy, that is, the 
per-protocol population, given the non-inferiority design. 
A secondary analysis will be performed on all randomised 
subjects according to the intention-to-treat principle, irre-
spective of adherence to the allocated dosing strategy.
Non-inferiority of the fixed dosing strategy is demon-
strated if the lower limit of the 95% CI of the difference 
in proportion of patients with effective haemostasis does 
not exceed (ie, is not lower than) 6%. If non-inferiority 
is demonstrated, a superiority analysis will follow. Next to 
95% CI of the risk difference, Fisher’s exact test will be 
used to establish superiority.
To determine homogeneity of the observed haemostatic 
effect over different subgroups of patients, subgroup anal-
yses are planned including patients with high versus low 
baseline INR (eg, cut-off 4.5) as well as analysis by type of 
bleeding and severity of bleed, brand of PCC and type of 
VKA.
Monitoring and auditing
The coordinating investigators will visit study centres approx-
imately once every 3 months, to discuss any issues, check on 
conduction of the study and discuss inclusion progress. Inde-
pendent data monitors will audit CRF data yearly.
Ethics and dissemination
The study will be conducted according to the principles 
of the Declaration of Helsinki (2013) and in accordance 
with the Dutch Medical Research Involving Human 
Subjects Act (WMO). As required by the WMO, patients 
are covered under the insurance for research subjects. The 
trial is registered in the European Union Clinical Trials 
Register under EUCTR2014-000392-33 (pre-results).
Study results will be published in an international journal, 
communicated to discipline-specific associations and 
presented at (inter)national meetings and congresses. The 
study was already announced in the Dutch Journal of Medi-
cine (NTvG) of May 2016 to invite centres to participate.21
As of October 2017, 127 patients have been included in 
7 participating centres.
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